Medical Condition News

RSS

Experts formulate research related to psychological adjustment and traumatic brain injury

Five U.S. federal agencies recently cosponsored a set of expert work groups to formulate common data elements for research related to psychological adjustment and traumatic brain injury (TBI).

19 Nov 2010

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

New University of Georgia research, published this week in the early online edition of the journal Proceedings of the National Academy of Sciences, has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.

19 Nov 2010

Genetic alterations may lead to thoracic aortic disease

Discovery of a fifth gene defect and the identification of 47 DNA regions linked to thoracic aortic disease are the subject of studies released this month involving researchers at The University of Texas Health Science Center at Houston (UTHealth).

19 Nov 2010

Doctors recommend drug holidays from bisphosphonates to enhance bone health

Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.

19 Nov 2010

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

Accumetrics, Inc., developer and marketer of the VerifyNow System, today announced that the GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) Trial found that in patients with high residual platelet reactivity, doubling the maintenance dose of clopidogrel did not reduce the risk of further ischemic events after percutaneous coronary intervention (PCI).

19 Nov 2010

ProvenCare to focus on potential problems in lung cancer patients

Northwestern Memorial Hospital is one of six national participants in a pilot study that will test whether operable lung cancer patients and their families have a smoother care experience and better outcomes by hardwiring data systems to reduce medical error and to reliably adhere to best practice standards.

19 Nov 2010

Ridge announces data from Clinical Experience Program on blood test for MDD disorder

Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from a Clinical Experience Program for its first-in-class, proprietary blood test for Major Depressive Disorder (MDD) will be presented during a poster session entitled Clinician Acceptance and Utility of a Multianalyte Biomarker Panel for Major Depressive Disorder (MDD) Diagnosis.

19 Nov 2010

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

State regulators and the Massachusetts nursing home industry are launching a campaign today to reduce the inappropriate use of antipsychotic medications for residents with dementia.

19 Nov 2010

Medicare committee recommends expensive drug for some prostate-cancer patients

A new treatment for prostate cancer called Provenge won a vote of confidence from a Medicare coverage advisory committee Wednesday, suggesting the federal program is likely to pay for the $93,000-per-patient medicine.

19 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

Glutaminase inhibitor: New potential target for brain tumors

Scientists at Johns Hopkins have identified a compound that could be used to starve cancers of their sugar-based building blocks. The compound, called a glutaminase inhibitor, has been tested on laboratory cultured, sugar-hungry brain cancer cells and, the scientists say, may have the potential to be used for many types of primary brain tumors.

19 Nov 2010

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Oncolytics Biotech Inc. announced today that the Children's Oncology Group (COG) intends to conduct a Phase I trial of REOLYSIN in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.

19 Nov 2010

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

Zalicus Inc. presented data today on its discovery of novel synergistic drug combinations for the treatment of cancer at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Meeting in Berlin, Germany on November 18, 2010.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

YM BioSciences Inc., today reported that the Phase I/II clinical trial for its orally available JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis has been expanded to five sites. Of the additional sites, the Stanford Cancer Center (Stanford, California) under Principal Investigator Jason Gotlib, MD has already commenced enrolling patients.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

Study finds adverse long term health effects of E coli infection

People who contract gastroenteritis from drinking water contaminated with E coli are at an increased risk of developing high blood pressure, kidney problems and heart disease in later life, finds a study published online in the British Medical Journal.

19 Nov 2010

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Ipsen announced today that its partner Inspiration Biopharmaceuticals, Inc. has initiated treatment of patients in the first of two phase III pivotal clinical studies of OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product, for the treatment of acquired hemophilia A, a rare, though potentially life-threatening bleeding disorder.

19 Nov 2010

Medical Condition News

Experts formulate research related to psychological adjustment and traumatic brain injury

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

Genetic alterations may lead to thoracic aortic disease

Doctors recommend drug holidays from bisphosphonates to enhance bone health

GRAVITAS Trial finds high dose of clopidogrel does not reduce risk of ischemic events

ProvenCare to focus on potential problems in lung cancer patients

Ridge announces data from Clinical Experience Program on blood test for MDD disorder

Mass. regulators and nursing homes fight inappropriate medicating; officials deal with Hawaii doctor shortage

Medicare committee recommends expensive drug for some prostate-cancer patients

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

Glutaminase inhibitor: New potential target for brain tumors

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

COG to conduct Phase I REOLYSIN trial in pediatric patients with solid tumors

Zalicus presents data on novel synergistic drug combinations for cancer at EORTC-NCI-AACR Symposium

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

YM BioSciences expands CYT387 Phase I/II clinical trial for myelofibrosis in five sites

Scientists discover bone matrix plays a vital role in tissue hardening

Study finds adverse long term health effects of E coli infection

Ipsen initiates patient treatment in phase III OBI-1 study for acquired hemophilia A

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News